New and Emerging Small Molecules: Making a Difference in UC (CME/CE Webcast)
hosted byMedEdicus LLCNew and Emerging Small Molecules: Making a Difference in UC (CME/CE Webcast) is organized by MedEdicus LLC.
Course opens: 04/13/2023
Course expires: 04/30/2024
Description:
Ulcerative colitis (UC) is a chronic inflammatory condition of the colorectum that is challenging to control and substantially degrades patient-related quality of life. Although treatments for UC have expanded in recent decades, limitations related to their safety, tolerability, and practicality of administration exist. Therapeutic agents in the form of oral small molecule drugs are either recently approved or in development and represent breakthroughs in the treatment UC that are anticipated to bring a significant shift to the treatment paradigm. This webcast is a recording of a live symposium that took place on Sunday, May 22, 2022. (Note: Upadacitinib has since been approved by the US Food and Drug Administration for use in patients with moderate to severe UC. At the time of this educational activity’s release, etrasimod is under investigation for its use in UC.) The desired results of this activity are to educate gastroenterology clinicians on updates in the treatment and management of patients with UC.
Learning Objectives:
After completing this activity, participants will be better able to:
• Review the mechanisms of action of small molecules for ulcerative colitis
• Describe features of oral small molecules for ulcerative colitis
• Summarize clinical evidence on small molecule drugs for ulcerative colitis
• Identify patients who would be good candidates for treatment with small molecule drugs
Additional details will be posted as soon as information is available.
